logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Acromegaly

    FiltersReset Filters
    10 results

    • bromocriptine mesylate

      (Bromocriptine mesylate)
      Zydus Pharmaceuticals USA Inc.
      Usage: Bromocriptine mesylate capsules are indicated for treating hyperprolactinemia-related disorders (e.g., amenorrhea, infertility, hypogonadism), acromegaly, and symptoms of Parkinson's disease. It may be used with levodopa to enhance efficacy and reduce side effects, especially in patients experiencing tolerance or "end of dose failure."

    • bromocriptine mesylate

      (Bromocriptine mesylate)
      Sandoz Inc
      Usage: Bromocriptine mesylate tablets are indicated for treating hyperprolactinemia-related dysfunctions (e.g., amenorrhea, infertility), acromegaly, and symptoms of Parkinson's disease. They help reduce tumor size in prolactin-secreting adenomas and enhance effects of levodopa in Parkinson's, while potentially reducing levodopa dosage and adverse reactions.

    • lanreotide acetate

      (LANREOTIDE ACETATE)
      Cipla USA Inc.
      Usage: Lanreotide Injection is indicated for the long-term treatment of acromegaly in patients not responding to surgery/radiotherapy, and for unresectable gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival. It also treats adults with carcinoid syndrome, reducing the need for short-acting somatostatin analogs.

    • octreotide acetate

      (octreotide acetate)
      Hainan Shuangcheng Pharmaceuticals Co., Ltd.
      Usage: Octreotide acetate injection is indicated for reducing growth hormone and IGF-1 levels in acromegaly, treating severe diarrhea and flushing from metastatic carcinoid tumors, and managing profuse watery diarrhea from vasoactive intestinal peptide tumors (VIPomas). Clinical trials did not demonstrate improvements in tumor size or growth rate.

    • octreotide acetate

      (octreotide acetate)
      Mylan Institutional LLC
      Usage: Octreotide acetate injection is used to reduce growth hormone and IGF-1 levels in acromegaly patients who have not responded to other treatments. It also treats severe diarrhea and flushing from metastatic carcinoid tumors and profuse watery diarrhea from vasoactive intestinal peptide tumors (VIPomas).

    • octreotide acetate

      (Octreotide Acetate)
      Meitheal Pharmaceuticals, Inc.
      Usage: Octreotide Acetate Injection is indicated for managing acromegaly in patients unresponsive to other treatments, treating severe diarrhea and flushing from metastatic carcinoid tumors, and addressing profuse watery diarrhea from vasoactive intestinal peptide tumors (VIPomas). Clinical trials did not confirm its impact on tumor size or growth rate.

    • r-gene

      (Arginine Hydrochloride)
      Pharmacia & Upjohn Company LLC
      Usage: R-Gene® 10 is indicated as an intravenous stimulant for the release of human growth hormone (HGH) to diagnose pituitary function in conditions like panhypopituitarism, dwarfism, and acromegaly. It aids in confirming HGH reserve deficiencies when previous tests indicate potential issues. Follow-up testing may be required.

    • sandostatin lar depot

      (octreotide acetate)
      Novartis Pharmaceuticals Corporation
      Usage: SANDOSTATIN LAR DEPOT is indicated for long-term maintenance therapy in acromegaly, and to treat severe diarrhea associated with metastatic carcinoid tumors and VIP-secreting tumors (VIPomas) in patients who have tolerated initial treatment with Sandostatin Injection.

    • somatuline depot

      (lanreotide acetate)
      Ipsen Biopharmaceuticals, Inc.
      Usage: SOMATULINE DEPOT is indicated for long-term treatment of acromegaly, unresectable gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and carcinoid syndrome in adults. It aims to normalize growth hormone levels, improve progression-free survival in GEP-NETs, and reduce the need for short-acting somatostatin analog rescue therapy in carcinoid syndrome.

    • somavert

      (pegvisomant)
      Pharmacia & Upjohn Company LLC
      Usage: SOMAVERT is indicated for treating acromegaly in patients with inadequate responses to surgery or radiation, or when these therapies are unsuitable. The aim of treatment is to normalize serum insulin-like growth factor-1 (IGF-1) levels.